Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-79.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.36 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -147.64% |
| Return on Assets (Trailing 12 Months) | -124.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.45 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.45 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.18 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.62 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 33.19M |
| Free Float | 26.32M |
| Market Capitalization | $13.92M |
| Average Volume (Last 20 Days) | 4.38M |
| Beta (Past 60 Months) | 0.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 45.24% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |